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Abstract
Mesenchymal stromal cells (MSCs) from different sources represent a heterogeneous 
population of proliferating non-differentiated cells that contain multipotent stem cells 
capable of originating a variety of mesenchymal cell lineages. By using Ca2+ imaging and 
the Ca2+ dye Fluo-4, we studied MSCs from the human adipose tissue and examined Ca2+ 
signaling initiated by a variety of GPCR ligands, focusing primarily on adrenergic and 
purinergic agonists. Being characterized by a relative change of Fluo-4 fluorescence, ago-
nist-induced Ca2+ responses were generated in an “all-or-nothing” fashion. Specifically, 
at relatively low doses, agonists elicited undetectable responses but initiated quite simi-
lar Ca2+ transients at all concentrations above the threshold. The inhibitory analysis and 
Ca2+/IP3 uncaging pointed at the phosphoinositide cascade as a pivotal pathway respon-
sible for agonist transduction and implicated Ca2+-induced Ca2+ release (CICR) in shaping 
agonists-dependent Ca2+ signals. Altogether, our data suggest that agonist transduction 
in MSCs includes two fundamentally different stages: an agonist initially triggers a local, 
gradual, and relatively small Ca2+ signal, which next stimulates CICR to accomplish 
transduction with a large and global Ca2+ transient. By involving the trigger-like mecha-
nism CICR, a cell is capable of generating Ca2+ responses of virtually universal shape and 
magnitude at different agonist concentrations above the threshold.
Keywords: Ca2+ signaling, G-protein coupled receptors, calcium-induced calcium 
release, IP
3
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1. Introduction
Mesenchymal stromal cells (MSCs) are described as a heterogeneous cellular pool that 
includes immature cells responsible for the replenishment of supportive and connective tis-
sues due to their capability of maintaining self-renewal and multipotent differentiation [1–3]. 
By unique biologic properties, cultured MSCs from different sources attract sufficient interest 
in the fields of regenerative medicine and immunotherapy [4–6]. Despite evident progress in 
MSC biology spurred by the therapeutic potential of these cells, current knowledge on their 
receptor and signaling systems remains scarce. Evidence exists that MSCs are capable of sens-
ing complex extracellular cues, including hormones, cytokines, and nucleotides [7, 8]. This 
implies that MSCs employ multiple surface receptors and signaling pathways to adjust their 
physiological functions to specific tissue microenvironment.
Here, we studied MSCs derived from the human adipose tissue and examined Ca2+ signaling 
initiated by a variety of agonists of G-protein coupled receptors (GPCRs). We specifically 
focused on adrenergic and purinergic signaling systems that attracted us for the following 
reasons. It has been known for a long time that noradrenaline released by sympathetic nerves 
regulates distinct physiological processes in the adipose tissue such as lipid and glucose 
metabolism and secretion of distinct signaling molecules, including adipocytokines and cyto-
kines [9]. Hence, MSCs that reside in the adipose tissue can be subjected to the action of nor-
adrenaline and factors released by adipocytes on adrenergic stimulation. Purinergic agonists 
have been documented as an important factor determining MSC fate [7, 8, 10–12]. Reportedly, 
ATP serves both as an adipogenic regulator and an osteogenic factor, while its downstream 
product adenosine switches off adipogenic differentiation and promotes osteogenesis [13, 
14]. Damaged tissues are an abundant source of extracellular ATP that may be converted by 
extracellular nucleotidases to ADP and eventually to adenosine [15]. It therefore might be 
expected that MSCs are exposed to and regulated by nucleotides and adenosine when these 
cells migrate in vivo or are transplanted ex vivo into an injured tissue.
The responsiveness to purines and pyrimidines is widespread among eukaryotic cells, 
which express numerous purinoreceptors from the P1 and P2 families. The P1 subgroup 
includes four G-protein-coupled receptors (A
1
, A2A, A2B, A3) recognizing adenosine as an endogenous agonist [16]. The more diverse P2 family is composed of ionotropic P2X and 
metabotropic P2Y receptors. P2X receptors are cationic channels specifically gated by ATP, 
while P2Y receptors are activated by multiple purine and pyrimidine nucleotides or by 
sugar nucleotides and couple to intracellular second messenger pathways by heteromeric 
G proteins [17, 18]. In mammals, seven genes encode P2X subunits (P2X
1–7
) that can form 
homo- and heterotrimeric cation channels with noticeable Ca2+ permeability [19, 20]. The 
P2Y subfamily includes eight members (P2Y1,2,4,6,11,12,13,14), which are distinct by ligand speci-ficity and coupling to downstream signaling pathways, including the ubiquitous phos-
phoinositide cascade [17, 18].
Nine genes encode human adrenoreceptors, which all belong to the GPCR superfamily and 
compose three distinctive subgroups, including three α
1
 (α1A, α1B, α1D), three α2 (α2A, α2B, α2C), and three β (β
1
, β
2
, β
3
) receptor subtypes. Canonically, α
1
-adrenoreceptors couple to Gq and 
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are ubiquitously involved in Ca2+ signaling [21]. Although α
2
 isoforms widely regulate adeny-
lyl cyclase via G
i
, their coupling to phospholipase C (PLC) and Ca2+ mobilization has also 
been documented [22]. All three β-subtypes are linked to adenylyl cyclase by G
s
, although β
2
 
and β
3
 also couple to G
i
, and directly do not control intracellular Ca2+ [23]. Given that certain 
isoforms of adrenergic and purinergic receptors are coupled to Ca2+ mobilization in diverse 
cell types, we considered Ca2+ imaging as an adequate approach to detail purinergic and 
adrenergic transduction in MSCs.
2. Materials and methods
2.1. Cell isolation and culturing
MSCs of the first passage were obtained from the Faculty of Basic Medicine at Lomonosov 
Moscow State University. All procedures that involved human participants were performed 
in accordance with the ethical standards approved by the Bioethical Committee of the Faculty 
based on the 1964 Helsinki declaration and its later amendments. The study involved 21 
healthy (not suffered from infectious or systemic diseases and malignancies) individuals from 
21 to 55 years old, and informed consent was obtained from each participant.
Cells were isolated from subcutaneous fat tissue of healthy donors using enzymatic diges-
tion as previously described [24]. Briefly, the adipose tissue was extensively washed with 
two volumes of Hank’s Balanced Salt Solution (HBSS) containing 5% antibiotic/antimycotic 
solution (10,000 units of penicillin, 10,000 μg of streptomycin, and 25 μg of Amphotericin B 
per mL; HyClone), fragmented, and then digested at 37°C for 1 h in the presence of colla-
genase (200 U/ml, Sigma-Aldrich) and dispase (10 U/ml, BD Biosciences). Enzymatic activity 
was neutralized by adding an equal volume of culture medium (HyClone™ AdvanceSTEM™ 
Mesenchymal Stem Cell Basal Medium for human undifferentiated mesenchymal stem cells 
containing 10% of HyClone™ AdvanceSTEM™ Mesenchymal Stem Cell Growth Supplement 
(CGS), 1% antibiotic/antimycotic solution (HyClone) and centrifuged at 200 g for 10 min. 
This led to the sedimentation of diverse cells, including MSCs, macrophages, lymphocytes, 
and erythrocytes, unlike adipocytes that remained floating. After removal of supernatant, a 
lysis solution (154 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA) was added to a cell pel-let to lyse erythrocytes, and cell suspension was centrifuged at 200 g for 10 min. Sedimented 
cells were resuspended in the MSC culture medium and filtered through a 100-μm 
nylon cell strainer (BD Biosciences). As indicated by flow [24], after isolation and overnight pre-
plating, the obtained cell population contained not only MSC cells that basically represented 
the most abundant subgroup but also admixed macrophages and lymphocytes. The two last 
cell subgroups were dramatically depleted by culturing for a week in the MSC culture medium 
and humidified atmosphere (5% CO
2
) at 37°C. The obtained MSC population was maintained 
at a subconfluent level (~80% confluency) and passaged using HyQTase (HyClone). By using 
the methodology described previously [25], cultured cells were demonstrated to differenti-
ate into the osteogenic, chondrogenic, and adipogenic directions, the finding confirming their 
multipotency. In experiments, MSCs of the second to fourth passages were usually used.
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2.2. Preparation of cells for Ca2+ imaging
Before assaying with Ca2+ imaging, cells were maintained in a 12-socket plate for 12 h in the 
medium described above but without antibiotics. For isolation, cells cultured in a 1-ml socket 
were rinsed twice with the Versene solution (Sigma-Aldrich) that was then substituted for 
200 μl HyQTase solution (HyClone) for 3–5 min. The enzymatic treatment was terminated 
by the addition of a 0.8 ml culture medium to a socket. Next, cells were resuspended, put 
into a tube, and centrifuged at 50 g for 45 s for moderate sedimentation. Isolated cells were 
collected by a plastic pipette and plated onto a photometric chamber of nearly 150 μl volume. 
The last was a disposable coverslip (Menzel-Glaser) with attached ellipsoidal resin wall. The 
chamber bottom was coated with Cell-Tak (BD Biosciences), enabling strong cell adhesion. 
Attached cells were then loaded with dyes for 20 min at room temperature (23–25°С) by add-
ing Fluo-4 AM (4 μM) and Pluronic (0.02%; all from Molecular Probes) to a bath solution. 
Loaded cells were rinsed with the bath solution for several times and kept at 4°C for 1 h prior 
to recordings. Generally, incubation of MSCs at low temperature stabilized intracellular Ca2+ 
and decreased a fraction of spontaneously oscillating cells.
2.3. Ca2+ imaging and uncaging
Experiments were carried out using an inverted fluorescent microscope Axiovert 135 equipped 
with an objective Plan NeoFluar 20x/0.75 (Zeiss) and a digital EMCCD camera LucaR (Andor 
Technology). Apart from a transparent light illuminator, the microscope was equipped with a 
handmade system for epi-illumination via an objective. The epi-illumination was performed 
using a bifurcational glass fiber. One channel was used for Fluo-4 excitation and transmitted 
irradiation of a computer-controllable light-emitting diode (LED) LZ1-00B700H (LED Engin). 
LED emission was filtered with an optical filter ET480/20x (Chroma Technology). Fluo-4 emis-
sion was collected at 535 ± 25 nm by using an emission filter ET535/50 m (Chroma Technology). 
Serial fluorescent images were usually captured every second and analyzed using Imaging 
Workbench 6 software (INDEC). Within the 1-s acquisition period, the 480 nm LED was 
switched on for only 200 ms, during which cell fluorescence was collected. This protocol 
allowed for minimizing photobleaching of Fluo-4 at a sufficiently high signal-to-noise ratio 
achievable by adjusting LED emission. This enabled us to reliably assay cell responsiveness to 
different compounds applied serially for up to 60 min. Deviations of cytosolic Ca2+ from the 
resting level were quantified by a relative change in the intensity of Fluo-4 fluorescence (ΔF/F
0
) 
recorded from an individual cell.
Another channel was connected to a pulsed solid laser TECH-351 Advanced (680 mW) (Laser-
Export, Moscow). This unit operated in a two harmonic mode and generated not only 351 nM 
UV light used for Ca2+ uncaging but also visible light at 527 nm. The last could penetrate 
into an emission channel through nonideal optical filters and elicit optical artifacts during 
uncaging. For Ca2+ or IP
3
 uncaging, cells were loaded with 4 μM Fluo-4-AM (Invitrogen) and 
4 μM NP-EGTA-AM (Invitrogen) or 4 μM caged-Ins(145)P3/PM (SiChem) + 0.02% Pluronic 
(Invitrogen) for 30 min at 23°С. The basic bath solution contained (mM): 110 NaCl, 5.5 KCl, 
2 CaCl
2
, 0.8 MgSO4, 10 glucose, 10 HEPES-NaOH, and pH 7.4 (≈270 Osm). When necessary, 
2 mM CaCl
2
 in the bath was replaced with 0.5 mМ EGTA + 0.4 mМ CaCl
2
, thus reducing free 
Ca2+ to nearly 260 nM at 23°С as calculated with the Maxchelator program (http://maxchelator.
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stanford.edu). In this low Ca2+ bath solution, the glucose concentration was increased to 
13 mM to keep osmolarity. All chemicals used in experiments described below were applied 
by the complete replacement of the bath solution in a 150-μl photometric chamber for nearly 
2 s using a perfusion system driven by gravity. The used salts and buffers were from Sigma-
Aldrich, and agonists and inhibitors were from Tocris.
3. Results
In a typical experiment, nearly a hundred of MSCs loaded with Fluo-4 resided in a photo-
metric camera, and their responsiveness to different ligands was assayed with Ca2+ imaging. 
Consistently with observations of others [3], functional heterogeneity was characteristic of a 
MSC population derived from each particular donor. Although a variety of GPCR agonists 
were found to stimulate Ca2+ signaling in MSCs, including ATP, ADP, noradrenaline or adren-
aline, acetylcholine or its analog carbachol, GABA, glutamate, serotonin, and UTP, only a 
relatively small group of cells in a given MSC population was specifically responsive to a par-
ticular agonist (Figure 1). Overall, nearly 103 MSCs were sequentially stimulated by multiple 
agonists applied at different combinations, and a particular cell was either irresponsive to all 
stimuli or responded to one, rarely two, particular compound (Figure 1A–C). ATP-sensitive 
cells composed the most abundant subgroup of 9–15% (12% on average), depending on MSC 
preparation (Figure 1B). The percentage of cells responsive to other agonists was on average: 
ADP—7.1, adenosine—8.7, carbachol—3.4, GABA—5, glutamate—1.2, noradrenaline—6.7, 
serotonin—6.6, and UTP—6 (Figure 1B). The more or less accurate analysis of distribution of 
MSC responsivity was performed for nucleotides. In designated experiments, wherein cells 
were sequentially stimulated by ATP, ADP, and UTP, 125 purinergic MSCs were assayed 
overall, and only 13 cells (10%) were found to respond to all three agonists at the indicated 
concentrations (Figure 1C). Both ATP and ADP stimulated Ca2+ signaling in 40 cells (32%) that 
did not respond to UTP; 33 cells (26%) preferred the ATP-UTP pair. In addition, 20, 9, and 7 
cells (16, 7, and 6%) responded exclusively to ATP, ADP, or UTP, respectively (Figure 1C).
Thus, the results presented above (Figure 1) clearly demonstrated that responsiveness to a 
given agonist varied from cell to cell. Note that GPCRs from most subfamilies, e.g. P2Y recep-
tors, can couple to several signaling pathways, depending on cellular context [26–29]. Hence, 
in cells nonresponsive in terms of Ca2+ signaling to a particular agonist, appropriate GPCRs 
might be either not expressed or not coupled to Ca2+ mobilization.
3.1. Dose dependence of MSC responses to adrenergic and purinergic agonists
In the present study, we focused on transduction of adrenergic and purinergic agonists 
capable of stimulating Ca2+ signaling in the MSC cytoplasm. We first aimed at evaluating dose 
dependencies of cellular responses to tested agonists. The analysis, which initially involved 
adrenergic transduction, revealed that Ca2+ responses varied with noradrenaline concentra-
tion in an “all-or-nothing” fashion. In other words, noradrenaline never caused detectable 
effects, when applied below 100 nM, but above the threshold of 100–200 nM, it elicited marked 
Ca2+ transients that were similarly shaped irrespective of agonist concentration (Figure 2A). 
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Since we expected to obtain a somewhat gradual dose dependence, we considered the pos-
sibility that at concentrations used, noradrenaline might elicit too high Ca2+ transients, which 
all saturated Fluo-4 fluorescence, thus appearing alike. However, the permeabilizing agent 
saponin (0.1 mg/mL) evoked marked Ca2+ signals that exceeded noradrenaline responses by 
the factor of 1.5–2 (17 cells; Figure 2A). These observations indicated conclusively that MSC 
responses to varied noradrenaline could not be equalized due to saturation of the Ca2+ dye. 
The further analysis of MSC responsivity pointed out that the “all-or-nothing” phenomenon 
Figure 1. Functional heterogeneity of MSCs from the human adipose tissue. (A) Concurrent monitoring of intracellular 
Ca2+ in five different cells loaded with Fluo-4. The selected agonists were applied as indicated by the horizontal lines 
above the upper trace. (B) Fractional distribution of 426 MSCs that responded to at least one from the following 
serially applied agonists, including 10 μM ATP (adenosine triphosphate), 3 μM ADP (adenosine diphosphate), 10 μM 
adenosine (Adeno), 20 μM carbachol (carb), 20 μM GABA (gamma-aminobutyric acid), 10 μM glutamic acid (Glut), 
0.5 μM noradrenaline (Nor), 10 μM serotonin (Ser), and 10 μM UTP (uridine triphosphate). (C) Distribution of MSC 
responsiveness to sequentially applied ATP (3 μM), ADP (3 μM), and UTP (10 μM) among a population of 125 cells, each 
being sensitive to at least one nucleotide.
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Figure 2. Agonists evoke Ca2+ responses in an “all-or-nothing” manner. (A–E) Monitoring of intracellular Ca2+ in five 
different MSCs serially stimulated by noradrenaline (A), ATP (B), ADP (C), UTP (D), and adenosine (E) at varied 
concentrations as indicated. In A, 0.1 mg/ml saponin was applied (arrow) in the end of the recording to demonstrate 
that Fluo-4 fluorescence was not saturated by Ca2+ bursts elicited by noradrenaline. (F) Summary of MSC responses 
to adenosine (n = 21; left panel), ADP (n = 16; middle panel) cells, and UTP (n = 11; right panel). For each assayed cell, 
a response to a particular agonist at low concentration was taken equal 1. The data are presented as mean ± S.D. The 
difference between responses to adenosine at 0.5 and 5 μM and to ADP at 1 and 30 μM ADP is statistically insignificant 
(student t-test, p < 0.05). The asterisk indicates significant difference (p < 0.05) of UTP responses at 3 and 50 μM. (G) 
Superimposed dose dependences of noradrenaline responses recorded from 10 cells that exhibited the threshold 
of 150 nM. For each cell, serial noradrenaline responses were normalized to a response to 1 μM noradrenaline. (H) 
Superimposed dose dependences of ATP responses recorded from eight cells that exhibited the threshold of 1 μM. In each 
case, ATP responses were normalized to a response to 10 μM ATP. In (G) and (H), each particular symbol corresponds 
to an individual cell.
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was intrinsic for the agonist-dependent Ca2+ signaling in general, including purinergic trans-
duction. In particular, submicromolar ATP was ineffective, while the nucleotide elicited Ca2+ 
transients in the MSC cytoplasm at 1–2 μM and higher (Figure 2B). The adenosine responses 
were characterized by the threshold of 0.2–0.3 μM and were similarly shaped at higher con-
centrations (9 cells; Figure 2C). For ADP- and UTP-responses, the threshold concentrations 
ranged within 0.5–2 and 3–6 μM, respectively. Although we did not carefully characterize 
MSC responses to adenosine, ADP, and UTP at widely and gradually varied concentrations, 
it appeared that dose-response curves for these agonists were also step-like. For example, Ca2+ 
transients of close magnitudes were usually elicited by adenosine at 0.5 and 5 μM (21 cells), 
ADP at 1 and 30 μM (16 cells), and UTP at 3 and 50 μM (11 cells) (Figure 2C–F).
In the case of noradrenaline and ATP, the dose dependence of MSC responses was carefully 
evaluated in designated experiments, wherein an agonist dose was gradually varied in a wide 
range of concentrations (Figure 2A, B). During this prolonged assay, responsiveness of many 
cells was liable to rundown, thus impeding the quantitative analysis. Overall, we identified 
21 cells that generated sufficiently robust responses to noradrenaline at 30 nM–10 μM with 
the threshold of 100–200 nM. Among them, 10 cells, which exhibited the same threshold of 
150 nM, were taken for the analysis. To compare different experiments, responses of each 
particular cell recorded at variable agonist concentrations were normalized to a response 
to 1 μM noradrenaline and superimposed as shown in Figure 2G, where different symbols 
correspond to individual cells. Despite some data scattering, normalized cellular responses 
were localized in the narrow range of 0.8–1.2 (Figure 2G), clearly demonstrating that in all 
cases, the dose dependence was a step-like rather than gradual. Similar inference came from 
the analysis of 32 ATP-sensitive cells that showed quite robust responses to the nucleotide 
gradually applied at 0.5–50 μM. Of them, nine MSCs generated rather similar Ca2+ signals at 
gradually increasing ATP doses with the threshold of 1 μM (Figure 2B, H).
One more notable feature of MSC responses was that Ca2+ transients were markedly post-
poned relative to a moment of agonist application. The characteristic time of response delay 
(τ
d
, Figure 3A) gradually decreased with noradrenaline and ATP concentration (Figure 3B, C). 
For instance, Ca2+ transients triggered by noradrenaline were retarded by 38–55 s at the 
threshold stimulation (Figure 3A, left response), whereas the delay was reduced to 17–26 s at 
the concentration of 1 μM and higher (Figure 3A, right response). The detailed assay of the 
dose-delay dependence was not carried out for the other agonists. Nevertheless, the compari-
son of MSCs responses obtained at low and saturated concentrations of adenosine, ADP, or 
UTP revealed a marked decrease in response delay as the agonist dose raised (Figure 3D). As 
discussed below, two distinct mechanisms are presumably responsible for specific dependen-
cies of the magnitude and delay of MSC responses on agonist concentration.
3.2. Agonist transduction involves the phosphoinositide cascade and Ca2+-induced 
Ca2+ release
In certain experiments, we analyzed coupling of adreno- and purinoreceptors to Ca2+ mobili-
zation in the MSC cytoplasm. When MSCs were pretreated with U73122 (2–5 μM), a poorly 
reversible inhibitor of PLC, all assayed cells became completely nonresponsive to tested ago-
nists, including noradrenaline (17 cells), ATP (39 cells), adenosine (11 cells), UTP (7 cells), and 
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ADP (5 cells) (Figure 4A–C, G–I). The inhibitory effect of U73122 on MSC responsiveness was 
apparently specific as the much less effective analog U73343 (2–5 μM) never canceled MSC 
responses to the nucleotides (Figure 4A–C, G, H). Moreover, the decrease of external Ca2+ 
from 2 mM to 260 nM weakly or negligibly affected Ca2+ transients elicited by ATP (26 cells), 
noradrenaline (31 cells), adenosine (7 cells), UTP (14 cells), and ADP (13 cells) (Figure 4C, D, 
G–I). Thus, the agonist-stimulated Ca2+ signaling in MSCs involved GPCRs that were basi-
cally coupled by the phosphoinositide cascade to Ca2+ release rather than to Ca2+ entry. Note 
also that the step-like dose dependence of ATP responses (Figure 2B, H) and their insignifi-
cant sensitivity to external Ca2+ (Figure 4G) indicated that P2X receptors could provide only a 
weak, if any, contribution to Ca2+ signaling triggered by ATP in the MSC cytoplasm.
Given the aforementioned effects of U73122 on MSC responses, there might be little doubt 
that the IP
3
 receptor, a common effector downstream of PLC [30], was involved in trans-
duction of assayed agonist. Expectedly, the IP
3
 receptor blocker 2-APB (50 μM) suppressed 
Ca2+ signaling initiated by ATP (21 cells), noradrenaline (19 cells), adenosine (5 cells), ADP (9 
cells), and UTP (10 cells) (Figure 4D–I)). In contrast, 50 μM ryanodine, a ryanodine receptor 
Figure 3. Dose dependence of agonist response delay. (A) Representative Ca2+ transients elicited by noradrenaline at 
100 nM (threshold concentration) and 500 nM in the same cell. These noradrenaline responses were delayed relative 
to the moment of agonist application by 55 and 16 s, respectively. The characteristic time of the response delay (τ
d
) 
was calculated as a time interval necessary for a Ca2+ transient to reach the half-magnitude. (B, C) Response lag versus 
noradrenaline (B) and ATP (C) concentration. The data were obtained from 10 adrenergic (Figure 2A, G) and 8 purinergic 
(Figure 2B, H) MSCs. (D) Delay of MSC responses to ADP (n = 16), UTP (n = 11), and adenosine (n = 21) at indicated 
concentrations. In (B–D), the data are presented as mean ± S.D.
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antagonist, was ineffective in all cases (Figure 4F–I). These findings suggested a negligible role 
for ryanodine receptors in agonist transduction. Consistently, their agonist caffeine (10 mM) 
insignificantly affected cytosolic Ca2+ in ATP-responsive MSCs (7 cells; Figure 4F). It should 
be noted that 2-APB blocks not only IP
3
 receptors but also a variety of Ca2+-entry channels 
[31–33]. Given however that MSC responsiveness to P2Y agonists insignificantly depended on 
external Ca2+ and therefore on Ca2+ influx (Figure 4G–I), we inferred that 2-APB exerted the 
inhibitory action mainly by targeting IP
3
 receptors.
The monotonic and gradual dependence of cellular responses on agonist concentration has 
been reported for a variety of cellular systems, including those that employ GPCRs coupling 
to Ca2+ mobilization [34–36]. In contrast, Ca2+ responses were generated by MSCs in an “all-or-
nothing” manner (Figure 2). This step-like dose dependence of response magnitude is poorly 
explicable and apparently inconsistent with the gradual relation between response delay 
and agonist concentration (Figure 3) if agonist transduction involves solely PLC-dependent 
Figure 4. Involvement of the phosphoinositide cascade in agonist transduction. (A–C) PLC inhibitor U73122 (2 μM) 
suppressed MSC responsivity to different agonists, including 0.5 μM noradrenaline (A), 1 μM adenosine (B), and 3 μM 
ADP (C), while its much less effective analogue U73343 (2 μM) was ineffective in all cases. (C, D) Reduction of external 
Ca2+ from 2 mM to 260 nM weakly or negligibly affected Ca2+ responses to agonists, including 3 μM ADP and 0.5 μM 
noradrenaline. Extracellular Ca2+ was not completely removed because MSCs poorly tolerated prolonged exposure to 
a Ca2+-free solution. (E, F) IP
3
 receptor blocker 2-APB (50 μM) reversibly suppressed MSC responses, particularly, to 
3 μM ADP, 10 μM UTP, and 5 μM ATP. (F) Caffeine and ryanodine, an agonist and antagonist of ryanodine receptors, 
respectively, negligibly affected cytosolic Ca2+ and ATP responsivity. (G–I) Summary of effects of indicated compounds 
and low Ca2+ on MSC responses to the tested agonists; n means the numbers of cells assayed in the particular case. The 
data are presented as mean ± S.D.; the asterisk indicates statistically significant difference (student t-test, p < 0.05).
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production of an IP
3
 burst and proportional Ca2+ release via IP
3
 receptors. To address this 
problem, we assumed that the agonist transduction occurred in two separated consecutive 
steps. Initially, an agonist produced a Ca2+ signal most likely being small, local, and gradu-
ally dependent on stimulus intensity. When exceeding the threshold, this local and poorly 
resolved Ca2+ signal pushed massive Ca2+-induced Ca2+ release (CICR) [37–40] to accomplish 
transduction with a large and global Ca2+ signal. By involving the trigger-like mechanism 
CICR, a cell generates Ca2+ responses of virtually universal shape and magnitude at different 
agonist concentrations above the threshold (Figure 2). Rising with agonist proportionally, the 
initial gradual Ca2+ signal reached a CICR threshold for the time that should have shortened 
with agonist concentration, thus underlying the gradual dose-delay dependence observed 
(Figure 3B, C).
To clarify functionality of the CICR mechanism in MSCs and its contribution to agonist 
responses, we used Ca2+ uncaging that allowed for generating as fast and intensive cytosolic 
Ca2+ bursts as necessary for initiating the CICR process. In designated experiments, MSCs 
were loaded with both Fluo-4 and NP-EGTA. The last is photolabile Ca2+ chelator with high 
affinity to Са2+ (Kd ~ 10−7 М), so that in a resting cell (~100 nm free Са2+), nearly half NP-EGTA 
molecules are bound to Са2+ ions. The absorption of ultraviolet (UV) light by NP-EGTA 
disrupts the coordination sphere responsible for Ca2+ binding, thus liberating Ca2+ions and 
producing a step-like increase in cytosolic Ca2+ [41]. Because a UV laser we employed for 
uncaging was in fact a biharmonic light source emitting at 351 and 527 nm, a light stimulus 
caused an optical artifact that was seen as a marked overshoot in a recording trace of cell 
fluorescence acquired at 535 ± 25 nm.
In this series, caged Ca2+ was released by moderate UV pulses during several seconds to 
somehow simulate the suggested Ca2+ signal initially produced by agonists in the MSC cyto-
plasm. As illustrated in Figure 5A, light stimuli triggered in adrenergic MSCs (n = 33) two 
fundamentally different types of Ca2+ responses. The relatively short, 2-s in the given case, 
UV pulse produced an optical artifact that was followed by a small Ca2+ jump without evident 
delay (Figure 5A, left panel, response 1 and right panel, thick line). This Ca2+ signal exhibited 
exponential relaxation presumably mediated by Ca2+ pumps. The sequential 4-s and 6-s UV 
flashes elicited biphasic Ca2+ transients of nonproportional magnitudes (Figure 5A, left panel). 
Indeed, compared to a 2-s UV pulse, one could expect 4- and 6-s light stimuli to liberate nearly 
twice and three times more Ca2+ ions, respectively. Meanwhile, 4-, 6-, and 8-s flashes usually 
triggered the similar Ca2+ transients that exceeded a response to a 2-s pulse by an order of 
magnitude (Figure 5A, left panel). None of the known Ca2+-dependent mechanisms but CICR 
could amplify and shape an initial Ca2+ signal produced by NP-EGTA photolysis in such a 
way (Figure 5A, right panel, response 1 vs. response 2). In addition, the representative cell 
(Figure 5A, left panel) was insensitive to 50 nM noradrenaline but similarly responded to 
the agonist at 0.5 and 1 μM concentrations. Similar results were obtained with other eight 
MSCs that tolerated prolonged serial stimulation with both UV and noradrenaline. Note that 
biphasic cell responses to light and noradrenaline were quite similar by shape and magnitude 
(Figure 5A, right panel, thin line 2 and circled line 3). Interestingly, light responses exhibited 
the delay that shortened with UV pulse duration (Figure 5, left panel). Similar experiments 
were performed with purinergic MSCs (n = 23) and basically identical results were obtained 
(Figure 5B). These findings support the idea that the delay of agonist responses (Figure 3) 
could be determined by the initial gradual Ca2+ signal.
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Similar to Ca2+ uncaging (Figure 5A), uncaging of IP
3
 produced agonist-like responses in puri-
nergic (n = 14) and adrenergic (n = 6) MSCs (Figure 5C). It was therefore possible that Ca2+ 
uncaging could simulate agonist-like responses by stimulating Ca2+-dependent PLC [42–44], 
which quickly generated a sufficient IP
3
 burst, thereby enhancing activity of IP
3
 receptors and 
triggering CICR. To verify this possibility, several adrenergic (n = 12) and purinergic (n = 7) 
MSCs loaded with NP-EGTA were subjected to Ca2+ uncaging in the presence of U73122. 
Although this PLC inhibitor expectedly rendered MSCs nonresponsive to the agonists, 
the cells normally responded to UV flashes (Figure 5D, E). The ineffectiveness of U73122 
(Figure 5D, E, H) provided strong evidence that PLC activation was not obligatory for gener-
ating light responses, thereby demonstrating that CICR initiated by UV flashes was directly 
stimulated by Ca2+ ions liberated from NP-EGTA.
Reportedly, ryanodine and inositol 1,4,5-trisphosphate (IP
3
) receptors, Ca2+-gated Ca2+ release 
channels operating in the endo/sarcoplasmic reticulum, are exclusively responsible for CICR 
Figure 5. Evidence for Ca2+-induced Ca2+ release in MSCs. (A) Left panel—Ca2+ transients resulted from Ca2+ uncaging 
in a NP-EGTA loaded cell by UV flashes of varied durations and Ca2+ responses to noradrenaline at the indicated 
concentrations. Right panel—The superimposition of the responses numbered in (A) as 1 (thick line), 3 (circles), and 
4 (thin line). (B) Left panel—Cellular responses to Ca2+ uncaging produced by a 4-s UV flash and to 5 μM ATP. Right 
panel—The superimposition of the light (thick line) and ATP (thin line) responses shown in the left panel. (C) ATP 
(5 μM) and uncaging of IP
3
 by a 2-s UV flash elicited similar responses in a cell loaded with caged-Ins(145)P3/PM. (D, 
E) PLC inhibitor U73122 (2 μM) dumped MSC responsiveness to 0.5 μM noradrenaline (D) and 5 μM ATP (E) but did 
not prevent agonist response-like Ca2+ transients resulted from Ca2+ uncaging by 4-s UV flashes. (F, G) 2-APB (50 μM) 
completely abolished biphasic agonist-like responses to Ca2+ uncaging by 4-s UV flashes, while 50 μM ryanodine was 
ineffective. In the experiments presented in (A–G), emission of a UV laser was weakened by the factor 10, so that Ca2+ 
uncaging should have lasted for 4 s to liberate as many Ca2+ ions as necessary for stimulating CICR. This gradual release 
of caged Ca2+ somewhat slowed the rising phase of a biphasic Ca2+ transient produced by CICR, thereby making a lag 
between a UV flash and a light response clearly visible. (H) Summary of effects of 2 μM U73122, 50 μM ryanodine, or 
50 μM 2-APB on Ca2+ transients elicited by 4-s UV flashes. The data are presented as mean ± SD; the asterisk indicates 
statistically significant difference (student t-test, p < 0.05).
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in apparently all cells [39, 42, 44]. To evaluate a relative contribution of IP
3
 and ryanodine 
receptors to CICR in MSCs, we examined effects of their antagonists on Ca2+ signals associ-
ated with Ca2+ uncaging. While 50 μM ryanodine was ineffective, 50 μM 2-APB dramatically 
and reversibly changed a shape and magnitude of UV responses in adrenergic (n = 16) and 
purinergic (n = 11) MSCs (Figure 5F–H). In the presence of 50 μM ryanodine, Ca2+ uncag-
ing elicited agonist-like biphasic Ca2+ responses that were delayed relative to stimulatory UV 
flashes (Figure 5F, G, 2nd responses). Thus, despite the inhibition of ryanodine receptors, Ca2+ 
uncaging was still capable of stimulating robust CICR in MSCs responsive to the agonists. 
With 50 μM 2-APB in the bath, a UV pulse entailed a brief Ca2+ jump that relaxed monotoni-
cally and was smaller by the factor 3–4 (Figure 5F, G, 3rd responses; Figure 5H). This indi-
cated that Ca2+ uncaging failed to initiate CICR with inhibited IP
3
 receptors. Moreover, when 
2-APB was removed to restore activity of IP
3
 receptors, a UV flash triggered a biphasic Ca2+ 
transient again (Figure 5F, G, 4th responses). These observations indicated that basically IP
3
 
receptors were responsible for CICR in adrenergic and purinergic MSCs.
3.3. Adrenoreceptor subtypes involved in Ca2+ signaling
Nine human genes encode adrenoreceptors, including α1Α, α1Β, α1D, α2Α, α2Β, α2C, β1, β2, and β
3
 isoforms [45]. Previously, we demonstrated that transcripts for α1Β-, α2Α-, and β2-adrenoreceptors were invariably present in total MSC preparations [24]. Given that both α
1
- 
and α
2
-adrenoreceptors are routinely coupled to PLC and Ca2+ mobilization in different cells 
[21, 22], either or both of these isoforms might be responsible for Ca2+ transients generated 
by MSCs in response to noradrenaline (Figure 2A). In contrast, β
2
-adrenoreceptors, which 
generally involve adenylyl cyclase as a downstream effector [23], could not be an essential 
contributor to Ca2+ signaling in adrenergic MSCs.
To uncover a role of the particular isoform, we performed recordings using agonists and 
antagonists specific for α
1
- or α
2
-adrenoreceptors. Overall, 35 noradrenaline-responsive cells 
were treated with phenylephrine/cirazoline and prazosin (α
1
-agonists and antagonist, respec-
tively) as well as with guanabenz/B-HT 933 and yohimbine (α
2
-agonists and antagonist, 
respectively). Most of them (29 cells, 83%) were irresponsive to phenylephrine (1–10 μM), 
and their noradrenaline responses were not inhibited by 10 μM prazosin. In contrast, guana-
benz (10–50 μM) and B-HT 933 (10 μM) were quite effective (Figure 6A). In particular, 50 μM 
guanabenz stimulated Ca2+ signaling in all noradrenaline-responsive MSCs (Figure 6A–C). 
Consistently, 2 μM yohimbine dumped cellular responses to noradrenaline and guanabenz 
(Figure 6A). Six cells (17%) were sensitive to both 10 μM phenylephrine and 50 μM guana-
benz (Figure 6B, C). These findings indicate that the α
2
-subtype, evidently α2Α, predominantly 
mediates Ca2+ signaling initiated by noradrenaline in MSCs, although in a minor MSC sub-
population, both α
1
- and α
2
-isoforms could be involved in adrenergic transduction.
3.4. Effects of isoform-specific agonists and antagonists of P2Y receptors
In mammalians, the P2Y subgroup includes eight GPCRs (P2Y1,2,4,6,11–14) that exhibit certain specificities to nucleotides, depending on species [18, 46]. The expression of purinoreceptors 
in MSCs was analyzed previously, and transcripts for multiple P2Y receptors were detected, 
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namely, P2Y
1
, P2Y
2
, P2Y4, P2Y6, P2Y11, P2Y13, and P2Y14, while P2Y12 transcripts were not detected in total MSC preparations [47]. Although this P2Y array is sufficient to account for 
MSC capability to detect ATP, ADP, and UTP, it was impossible to evaluate a contribution of a 
particular P2Y isoform based on MSC responses to these natural P2Y agonists (Figure 2B, E, F). 
To address this issue, we used isoform-specific P2Y agonists and antagonists.
The human P2Y family contains two ATP receptors, including specialized P2Y
11
 and also P2Y
2
 
that recognizes both UTP and ATP as full equipotent agonists [18]. Although also known as 
a partial P2Y
1
 agonist, ATP was hardly capable of stimulating P2Y
1
-signaling in MSCs at low 
micromolar concentrations due to much lower efficacy than ADP [48]. We tried to evaluate 
a contribution of P2Y
11
 and P2Y
2
 to MSC responsiveness to ATP. Among 181 MSCs assayed 
in this series, 169 cells (93%) became nonresponsive to ATP (3 μM) in the presence of 30 μM 
NF 340, a specific P2Y
11
 antagonist. These NF 340-sensitive cells did not respond to the P2Y
2
 
Figure 6. Sensitivity of MSCs to adrenergic agonists and antagonists. (A) In most (83%) of noradrenaline-sensitive 
MSCs, α2-receptor agonists B-HT 933 and guanabenz stimulated Ca2+ signaling in contrast to the α1-receptor agonists 
phenylephrine and cirazoline that were ineffective. Consistently, Ca2+ signaling stimulated in such cells by noradrenaline 
and guanabenz was canceled in the presence of the α2 antagonist yohimbine, while the α1 antagonist prazosin was 
ineffective. (B) Small subpopulation (17%) of noradrenaline-sensitive cells responded to both α2 and α1 agonists. 
(C) Responsiveness of 35 MSCs sequentially stimulated by 0.5 μM noradrenaline, 50 μM guanabenz, and 10 μM 
phenylephrine.
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agonist MRS 2768 (10 μM) (Figure 7A, cell 1 and Figure 7B). In a subpopulation of rare MSCs 
(12 cells) that were capable of generating Ca2+ transients on 3 μM ATP in the presence of NF 
340, 11 cells also responded to 10 μM MRS 2768 (Figure 7A, cell 2 and Figure 7B). Thus, MSCs 
that were insensitive to NF 340 presumably employed P2Y
2
 or both P2Y
2
 and P2Y
11
 to detect 
ATP.
While the P2Y
11
 antagonist was highly effective (Figure 7A, B), most ATP-sensitive MSCs 
were surprisingly nonresponsive to NF 546 (10 μM), the specific P2Y
11
 agonist reported to be 
even more effective than ATP [49]. Among 127 cells that responded to 3 μM ATP, 10 μM NF 
546 stimulated Ca2+ signaling solely in 9 cells (7%; Figure 7C, D). At the moment, we cannot 
provide any valid explanation for very low efficacy of NF-546 relative to ATP (Figure 7D). 
Perhaps, this synthetic ligand is a biased agonist that enables coupling of P2Y
11
 to the phos-
phoinositide cascade by involving only a certain G-protein type, which is absent or relatively 
less abundant in most of the MSCs.
Figure 7. Sensitivity of MSCs to agonists and antagonists of P2Y
2
 and P2Y
11
 receptors. (A) Representative responses of 
two concurrently assayed cells to ATP (3 μM) and to the P2Y
2
 agonist MRS 2768 (10 μM). The great majority (93%) of 
ATP-sensitive MSCs were rendered nonresponsive by 30 μM NF 340, a P2Y
11
 antagonist, and such cells never responded 
to 10 μM MRS 2768 (Cell 1). Uncommon cells that remained sensitive to ATP in the presence of 30 μM NF 340 responded 
to 10 μM MRS 2768 as well (Cell 2). (B) Responsiveness of 181 MSCs to 3 μM ATP and 10 μM MRS 2768 assayed in control 
and in the presence of NF 340. (C) Representative concurrent recordings from an ordinary cell insensitive to 10 μM NF 
546 (Cell 1) and from an occasional cell responsive to this specific P2Y
11
 agonist (n = 127; Cell 2). (D) Responsiveness of 
127 MSCs to 3 μM ATP and 10 μM NF 546.
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UTP is a full agonist for P2Y
2
 and P2Y4 that were identified in MSCs at the population level [47]. It therefore was unclear whether a particular cell employs either or both of these P2Y 
receptors for monitoring extracellular UTP. We analyzed the sensitivity of 95 UTP-responsive 
MSCs to MRS 2768 and MRS 4062, specific agonists of P2Y
2
 and P2Y4 receptors, respectively. Consistently with the analysis of ATP-responsive cells (Figure 7B), we found only 9 (9.5%) 
of 95 UTP-sensitive cells to react to 10 μM MRS 2768 (Figure 8A, cell 3 and Figure 8B). 
Figure 8. Sensitivity of UTP-responsive MSCs to P2Y
2
 and P2Y4 agonists. (A) Representative recordings from purinergic MSCs stimulated by UTP (10 μM), MRS 2768 (10 μM), and the agonists of P2Y4 receptor MRS 4062 (10 μM), in series. (B) Responsiveness of UTP-sensitive MSCs (n = 95) to MRS 2768 and MRS 4062.
Figure 9. Contribution of P2Y
1
 and P2Y
13
 to ADP responsiveness. (A) Representative MSC responses to 3 μM ADP and 
to the P2Y
1
 agonist MRS 2365 applied at 300 nM and 10 μM. All cells treated with 10 μM MRS 2179 (n = 65) became 
nonresponsive to 3 μM ADP. (B) When applied alone at 10 μM, antagonists of P2Y
1
 (MRS 2179) and P2Y
13
 (MRS 2211) 
inhibited responses of MSCs to 3 μM ADP (46 cells). (C) Summary of responses of 51 MSCs to 3 μM ADP in control and 
in the presence of MRS 2179 or MRS 2211.
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In contrast, 78 cells (82%) responded to 10 μM MRS 4062 (Figure 7A, cell 1 and Figure 7B). 
These findings suggested that predominantly P2Y4 was responsible for Ca2+ signaling evoked in MSCs by UTP, while P2Y
2
 was either expressed in a very small subpopulation of P2Y4-negative cells or not coupled to Ca2+ mobilization in a great majority of P2Y4-positive cells.
Extracellular ADP is detected by cells with P2Y
1
, P2Y
12
, and P2Y
13
. The analysis of ADP 
responsiveness was performed on 102 MSCs sensitive to 3 μM ADP (Figure 8A) that might 
be recognized by P2Y
1
 and/or P2Y
13
 receptors, given that P2Y
12
 transcripts were not found in 
MSCs. To evaluate a role of the P2Y
1
, 65 of 103 ADP-sensitive MSCs were treated with MRS 
2365, a highly potent and selective P2Y
1
 agonist that displays no activity at P2Y
12
 and P2Y
13
 
at submicromolar concentrations [50]. MRS 2365 was ineffective at 100–300 nM but triggered 
Ca2+ signaling in 16 (25%) of 65 MSCs at 10 μM (Figure 9A). Because MRS 2365 specifically 
stimulates P2Y
1
 with EC
50
 ~ 1 nM [50], this agonist might bring about a nonspecific action 
at 10 μM. On the other hand, MRS 2179 (10 μM), a P2Y
1
 antagonist with IC
50
 = 0.15 μM [49], 
inhibited ADP responses in all MRS 2365-treated MSCs (65 cells; Figure 9A). Given that other 
P2Y receptors were hardly inhibited by 10 μM MRS 2179 [49], the observed effects of the 
specific agonist and antagonist of the P2Y
1
 receptor were rather inconsistent. To reconcile 
these contradictory findings, we considered the possibility that both P2Y
1
 and P2Y
13
 should 
have been activated by ADP concurrently to mobilize Ca2+ in MSCs. If so, nanomolar MRS 
2365 was ineffective, activating solely P2Y
1
, while 10 μM MRS 2365 stimulated activity of both 
P2Y
1
 and P2Y
13
 [50], thus triggering Ca2+ signaling in MSCs. This concept predicted that MSCs 
would be unable to respond to ADP if either P2Y
1
 or P2Y
13
 was inhibited. In line with this idea, 
we assayed sensitivity of 51 ADP-responsive MSCs to both MRS 2179 (10 μM) and MRS 2211 
(10 μM), a P2Y
13
 antagonist. It turned out that either of these compounds rendered each of 51 
assayed cells nonresponsive to ADP (Figure 9B, C). Altogether, our findings (Figure 9A–C) 
indicated that only those MSCs, which functionally expressed both P2Y
1
 and P2Y
13
 receptors, 
were capable of generating robust Ca2+ responses to ADP.
4. Discussion
Virtually in all cell types, extracellular cues can mobilize intracellular Ca2+ to regulate a variety 
of diverse cellular functions, such as fertilization, proliferation, secretion, metabolism, gene 
expression, mobility, and muscle contraction. How can the Ca2+ ion, a chemically simple sub-
stance, control so many different physiological processes? The plausible explanation comes 
from the versatility of Ca2+ signaling mechanisms that can mediate Ca2+ signals with vari-
able kinetics, amplitude, duration, and spatial patterning, depending on cellular context and 
stimulation [30, 37, 42].
Transduction of multiple agonists involves GPCRs coupled to PLCβ1–4 isoforms that hydro-lyze the precursor lipid phosphatidylinositol 4,5-bisphosphate to produce two second mes-
sengers, IP
3
 and diacylglycerol. The primary mode of action of IP
3
 is to bind to IP
3
 receptors 
and release Ca2+ from the endoplasmic reticulum (ER) [30, 51, 52]. Three different isoforms of 
the IP
3
 receptor have been identified (IP
3
R1, IP
3
R2, and IP
3
R3) and shown to serve as a tetra-
meric IP
3
-gated Ca2+ channel [30, 51–53]. IP
3
R1, IP
3
R2, and IP
3
R3 are distinct by physiological 
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properties, thus allowing cells to generate specific Ca2+ signals with different spatial and tem-
poral characteristics to control diverse cellular functions [30, 52]. In addition to IP
3
, Ca2+ is 
the primary coregulator of IP
3
 receptors [30, 51, 52, 54]. The full activation of the IP
3
 receptor 
occurs when IP
3
 has occupied the IP
3
-binding domains on all four subunits [55]. This is associ-
ated with a conformational change, which sensitizes the Ca2+-binding site. The binding of 
cytosolic Ca2+ to this site markedly increases the open probability of the IP
3
 receptor channel 
[54], so that Ca2+ ions released from the ER can additionally stimulate activity of IP
3
 receptors. 
This positive feedback mediates CICR. Meanwhile, the action of cytosolic Ca2+ is bimodal: 
stimulating IP
3
 receptors at low levels, Ca2+ becomes inhibitory above 300 nm [54]. This mul-
timodal control of the IP
3
 receptor by IP
3
 and Ca2+ is central to various aspects of intracellular 
Ca2+ signaling [30, 52].
In the present work, we studied MSCs from the human adipose tissue and examined intra-
cellular Ca2+ signaling initiated by certain GPCR agonists, including adenosine, ATP, nor-
adrenaline, and some others. Although all first messengers tested here were effective, only a 
relatively small MSC group responded to a particular agonist. These specifically responsive 
cell subpopulations overlapped weakly or negligibly, depending on agonists (Figure 1). This 
finding is hardly surprising in light of a widely accepted idea that a MSC population from dif-
ferent sources represents a heterogeneous mixture of diverse cells, including multipotent and 
more committed progenitor cells [1, 3, 56, 57]. Yet, cultured MSCs are not synchronized and 
dwell in different phases of the cell cycle. It therefore might be expected that divergent intra-
cellular signaling is inherent in a MSC population containing both proliferating and quiescent 
cells. The aforementioned factors could underlie intrinsic heterogeneity of a MSC popula-
tion discussed previously [56, 57]. It also should be mentioned that most of assayed MSCs 
were found by us nonresponsive to a particular agonist solely in terms of Ca2+ signaling that 
necessitated coupling of appropriate GPCRs to Ca2+ mobilization. Meanwhile, many GPCR 
isoforms are in fact promiscuous in that they may be coupled to a variety of downstream 
signaling pathways, depending on G-proteins involved. For instance, the P2Y1,2,4,6,11 subtypes of purinoreceptors are canonically coupled by Gq/G11 to the phosphoinositide cascade and 
Ca2+ mobilization, whereas P2Y12,13,14 control cAMP production by inhibiting adenylyl cyclase through G
i
/G
o
. The unique capability of P2Y
11
 is to stimulate G
s
 [18]. In addition, apart from 
ubiquitous coupling to PLC and adenylyl cyclase, P2Y receptors can also engage effectors 
such as MAP, PI3, Akt, and PKC kinases; small G-proteins; NO synthase; transactivation of 
growth factor receptors; and some others [26–29]. Hence, a fraction of MSCs sensitive to a 
given agonist might be in fact much more abundant than that evaluated by Ca2+ imaging 
(Figure 1B, C), because the tested compounds could stimulate not only Ca2+ mobilization but 
also other signaling events.
The agonist-dependent Ca2+ signaling in MSCs was mostly detailed by us for noradrenaline 
and certain nucleotides. By using subtype-specific agonists and antagonists, it was shown that 
mainly a
2
-adrenoreceptors mediated Ca2+ mobilization triggered by noradrenaline in adrener-
gic MSCs (Figure 6). In purinergic MSCs, presumably P2Y
11
 serves as a primary ATP receptor 
(Figure 7), UTP responsiveness is largely mediated by P2Y4 (Figure 8), while both P2Y1 and P2Y
13
 are involved in detecting ADP (Figure 9). The responsivity of MSCs to noradrenaline 
and ATP and apparently to adenosine, ADP, and UTP exhibited a peculiar dose dependence: 
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undetectably affecting intracellular Ca2+ below the cut-off concentration, a particular agonist 
initiated Ca2+ transients that were large and quite similarly shaped at all doses above the 
threshold (Figure 2). In contrast to this step-like dose-response curve, the dependence of 
response delay on agonist concentration was gradual (Figure 3). The inhibitory analysis and 
Ca2+ uncaging approach showed that agonist transduction universally involved the classical 
phosphoinositide cascade and CICR mechanism (Figures 4 and 5) that employed IP
3
 receptors 
rather than ryanodine receptors (Figures 4E, F and 5F, G).
To reconcile the “all-or-nothing” dose-response curve and gradual dose-delay dependence, 
we surmised that agonist-evoked Ca2+ signaling in MSCs includes two different but coupled 
stages. Primarily, agonists stimulate IP
3
 production, activation of IP
3
 receptors, and gen-
eration of an initial, presumably local and gradual Ca2+ signal. Next, this local Ca2+ signal 
stimulates CICR that produces a global Ca2+ signal. Some evidence suggests that the Ca2+ store 
responsible for the initial Ca2+ signal may be physically separated from the Ca2+ store that 
provides CICR. Indeed, when cells were overloaded with NP-EGTA due to the twofold excess 
of NP-EGTA-AM concentration compared to the standard loading protocol (see Methods), 
a MSC population became poorly sensitive to ATP. However, several UV flashes usually 
rendered MSC responsive (Figure 10). Presumably, overloading with NP-EGTA excessively 
increased the Ca2+-buffering capacity of the cell cytoplasm, thereby significantly diminish-
ing the initial agonist-induced Ca2+ signal and its speed. The photodistraction of NP-EGTA 
decreased exogenous Ca2+ buffer to a physiologically more relevant level, thus recovering 
MSC responsiveness to ATP. Note that in line with multiple reports, relatively slow Ca2+ buf-
fer EGTA is unable to cancel Ca2+-dependent processes mediated by local intracellular Ca2+ 
signals. For instance, 1 mM EGTA does not prevent activation of Ca2+-gated BK channels by 
Ca2+ transients originated by both Ca2+ influx via voltage-gated Ca2+ channels and Ca2+ release 
stimulated by muscarine [58]. By analogy and based on the observation that Ca2+ uncaging 
was still capable of triggering CICR in MSCs overloaded with NP-EGTA (Figure 10), we sug-
gested that NP-EGTA, slow Ca2+ buffer [59], could hardly repeal stimulation of IP
3
 receptors 
by Ca2+ ions released through this IP
3
-gated conduit. If so, the Ca2+ store and IP
3
 receptor 
pool mediating CICR should be spatially separated from agonist-dependent machinery that 
Figure 10. MSCs overloaded with NP-EGTA became nonresponsive to agonists. In this particular experiment, 76 cells, 
which have been pre-incubated with 4 μM Fluo-4-AM and 8 μM instead of 4 μM NP-EGTA-AM, were simultaneously 
assayed. None of these cells generated Ca2+ responses to the first application of 5 μM ATP. As exemplified by the 
presented fluorescence trace, two sequential Ca2+ uncaging by 4-s UV flashes rendered 7 of 76 cells sensitive to 5 μM 
ATP. The same phenomenon was observed in two more similar experiments.
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generates an initial, local, and gradual Ca2+ signal. Otherwise, it is difficult to explain why in 
cells overloaded with NP-EGTA, agonist responses disappeared contrary to light responses 
associated with Ca2+ uncaging (Figure 10).
5. Conclusion
Note in conclusion that the specific features of agonist responses, including kinetics and 
magnitude, all-or-nothing behavior and gradual dose-response delay were correctly repro-
duced by Ca2+ signals elicited by Ca2+ uncaging (Figure 5). This supports the idea that 
agonist-evoked Ca2+ signaling in MSCs includes two different but coupled stages. Initially, 
agonists stimulate coupling of suitable GPCRs via appropriate G-proteins to PLC, thus trig-
gering IP
3
 production, activation of IP
3
 receptors (IP
3
Rgrad) followed by the release of Ca2+ 
ions from Ca2+ store. This machinery generates an initial, presumably local and gradual Ca2+ 
signal (Figure 11). When exceeding the threshold, this local Ca2+ signal stimulates CICR that 
is mediated by IP
3
 receptors (IP
3
RCICR) presumably located in another, spatially separated 
Ca2+ store. By involving the trigger-like mechanism CICR, a cell generates Ca2+ responses 
of virtually universal shape and magnitude at different agonist concentrations above the 
Figure 11. Working model of agonist transduction in MSCs. The binding of agonists to GPCRs stimulates PLC-dependent 
hydrolysis of PIP
2
 to DAG and IP
3
. The consequent activation of IP
3
 receptors (IP
3
Rgrad) mediates Ca2+ release from 
related Ca2+ store, producing an initial Ca2+ signal that gradually rises with agonist concentration (red curve). As soon 
as this signal reaches the threshold level (dotted line), the process determining agonist-dependent delay of a cellular 
response, one stimulates IP
3
 receptors of another type (IP
3
RCICR) in separated Ca2+ store and triggers CICR. This provides a significant amplification mechanism that finalizes transduction with a large and global Ca2+ signal (blue curve).
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cut-off dose. Of course, the presented model is a simplification of the actual transduction 
process, and roles for other common contributors to intracellular Ca2+ signaling, including 
Ca2+ pumps, mitochondria, Ca2+ buffer as well as Ca2+-dependent enzymes and ion channels, 
remain to be elucidated.
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